Q3-osavuosiraportti
Vain PDF
8 päivää sitten
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
25 988
Myynti
Määrä
17 981
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | NON | NON | ||
| 3 033 | DDB | NON | ||
| 2 000 | DDB | NON | ||
| 3 012 | NON | AVA | ||
| 2 083 | NON | NON |
Ylin
0,29VWAP
Alin
0,226VaihtoMäärä
0 13 586
VWAP
Ylin
0,29Alin
0,226VaihtoMäärä
0 13 586
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 5 033 | 0 | +5 033 | 0 |
| Nordea Bank Abp | 0 | 20 | −20 | 0 |
| Nordnet Bank AB | 8 553 | 10 118 | −1 565 | 5 085 |
| Avanza Bank AB | 0 | 3 448 | −3 448 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 0 | 3 448 | −3 448 | 0 |
| Nordnet Bank AB | 8 553 | 10 118 | −1 565 | 5 085 |
| Nordea Bank Abp | 0 | 20 | −20 | 0 |
| Danske Bank A/S | 5 033 | 0 | +5 033 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 27.10. | |
| 2025 Ylimääräinen yhtiökokous | 21.10. | |
| 2025 Q2-osavuosiraportti | 25.8. | |
| 2025 Q1-osavuosiraportti | 23.5. | |
| 2025 Q1-osavuosiraportti | 28.4. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·21.10. · MuokattuDanCann Pharma is now doing this legally withdrawing and using other money and their own money on shares? without bankruptcy Cannabis company Dancann Pharma is traded today, February 24, on the Spotlight Stock Market after a reverse split. The terms are 1:1,000, meaning that one thousand existing shares are combined into one share. The share is traded with an unchanged short name DANCAN and a new Isin code.·21.10.Minutes of the Extraordinary General Meeting of DanCann Pharma A/S Tue, Oct 21, 2025 10:00 CETReport this content Minutes of the Extraordinary General Meeting of DanCann Pharma A/S, CVR-no. 39 42 60 05 ("the Company") On October 21, 2025 at 09:00 (CET), an Extraordinary General Meeting of the Company was held at the Company's address, Rugvænget 5, 6823 Ansager. The agenda for the Extraordinary General Meeting was as follows: Proposal for approval of the Board of Directors' resolution of October 6, 2025 on the voluntary delisting of the Company's shares from the Spotlight Stock Market and adoption of amendments to the Articles of Association. (proposed by the Board of Directors) Attorney Michael Kristensen was appointed as chairman of the General Meeting in accordance with section 11.20 of the Company's Articles of Association. The Chairman announced that the general meeting had been duly convened when the notice of the extraordinary general meeting was given on 6 October 2025. The Chairman described the formal requirements for the notice and concluded that these had been met. The Chairman stated that a total of 75,000 votes were represented at the general meeting, all of which were represented by shareholders in physical attendance. The Chairman concluded that the general meeting had a quorum in relation to the agenda. Re 1 The Company's Board of Directors has resolved on 6 October 2025 to submit an application to Spotlight Stock Market for voluntary delisting of the Company's shares from Spotlight Stock Market in accordance with section 6.3 of the Spotlight Stock Market Regulations, provided that this extraordinary general meeting approves it by a majority of at least 2/3 of the votes cast and 2/3 of the share capital represented at the general meeting. It was therefore proposed that the extraordinary general meeting (i) approve the board of directors' decision to apply for voluntary delisting of the Company's shares from the Spotlight Stock Market and (ii) adopt the amendments to the articles of association set out in the addendum to the draft new articles of association attached as Appendix 1 (the said amendments enabling delisting of the Company's shares). The proposed amendments to the articles of association enable delisting of the Company's shares, and these ensure, among other things, that the Company's shares can be freely traded also after delisting. It was noted that the board of directors expects to submit an application for delisting of the Company's shares to the Spotlight Stock Market on 7 January 2026. Assuming that the Spotlight Stock Market approves the application for delisting, the last trading day is expected to be 22 January 2026. The shares may be traded on the Spotlight Stock Market in accordance with the rules of the Spotlight Stock Market up to and including the last trading day. It was noted that a delisting of the Company's shares from trading on the Spotlight Stock Market will mean that the Company's shares cannot be traded on the Spotlight Stock Market, and trading in the Company's shares will take place over-the-counter ("OTC"). Provisional schedule for the delisting: January 7, 2026 Application for delisting submitted to the Spotlight Stock Market January 8, 2026 Spotlight Stock Market approves the delisting and announces the last day of trading in the Company's shares on the Spotlight Stock Market January 8, 2026 The Company publishes a press release regarding the approval of the delisting and the last day of trading January 22, 2026 Expected last day of trading for the Company's shares on the Spotlight Stock Market The proposal was adopted unanimously and with all votes cast. ------ The meeting was closed. Chairman of the General Meeting: _______________________________ Michael Kristensen
·17.10.I wonder if it's still up and selling and taking the loss we're now taking. Or should we have ice in our stomachs.·17.10.What is it like when you sell at a loss, in addition to having bet incorrectly?
·15.10.Wonder how much the pharmaceutical industry paid them to shut down🤔?·15.10.The accounts speak for themselves - the company has not been sustainable in a single account and lives off other people's money. But we can blame the pharmaceutical industry :). Just remember that the company here operates under licenses and requirements from the Danish Medicines Agency and charges sky-high prices for their products - they are part of the industry themselves.
·14.10.Theft of over 100 million of the shareholders' money, it's too easy but well done by Jeppe and his henchmen.
·14.10.They should be behind bars, it's disgusting that idiots should be making 100 million on fraud
·13.10.I think it will end with a purchase offer All the shares now cost only 878,000 kr.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
Vain PDF
8 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·21.10. · MuokattuDanCann Pharma is now doing this legally withdrawing and using other money and their own money on shares? without bankruptcy Cannabis company Dancann Pharma is traded today, February 24, on the Spotlight Stock Market after a reverse split. The terms are 1:1,000, meaning that one thousand existing shares are combined into one share. The share is traded with an unchanged short name DANCAN and a new Isin code.·21.10.Minutes of the Extraordinary General Meeting of DanCann Pharma A/S Tue, Oct 21, 2025 10:00 CETReport this content Minutes of the Extraordinary General Meeting of DanCann Pharma A/S, CVR-no. 39 42 60 05 ("the Company") On October 21, 2025 at 09:00 (CET), an Extraordinary General Meeting of the Company was held at the Company's address, Rugvænget 5, 6823 Ansager. The agenda for the Extraordinary General Meeting was as follows: Proposal for approval of the Board of Directors' resolution of October 6, 2025 on the voluntary delisting of the Company's shares from the Spotlight Stock Market and adoption of amendments to the Articles of Association. (proposed by the Board of Directors) Attorney Michael Kristensen was appointed as chairman of the General Meeting in accordance with section 11.20 of the Company's Articles of Association. The Chairman announced that the general meeting had been duly convened when the notice of the extraordinary general meeting was given on 6 October 2025. The Chairman described the formal requirements for the notice and concluded that these had been met. The Chairman stated that a total of 75,000 votes were represented at the general meeting, all of which were represented by shareholders in physical attendance. The Chairman concluded that the general meeting had a quorum in relation to the agenda. Re 1 The Company's Board of Directors has resolved on 6 October 2025 to submit an application to Spotlight Stock Market for voluntary delisting of the Company's shares from Spotlight Stock Market in accordance with section 6.3 of the Spotlight Stock Market Regulations, provided that this extraordinary general meeting approves it by a majority of at least 2/3 of the votes cast and 2/3 of the share capital represented at the general meeting. It was therefore proposed that the extraordinary general meeting (i) approve the board of directors' decision to apply for voluntary delisting of the Company's shares from the Spotlight Stock Market and (ii) adopt the amendments to the articles of association set out in the addendum to the draft new articles of association attached as Appendix 1 (the said amendments enabling delisting of the Company's shares). The proposed amendments to the articles of association enable delisting of the Company's shares, and these ensure, among other things, that the Company's shares can be freely traded also after delisting. It was noted that the board of directors expects to submit an application for delisting of the Company's shares to the Spotlight Stock Market on 7 January 2026. Assuming that the Spotlight Stock Market approves the application for delisting, the last trading day is expected to be 22 January 2026. The shares may be traded on the Spotlight Stock Market in accordance with the rules of the Spotlight Stock Market up to and including the last trading day. It was noted that a delisting of the Company's shares from trading on the Spotlight Stock Market will mean that the Company's shares cannot be traded on the Spotlight Stock Market, and trading in the Company's shares will take place over-the-counter ("OTC"). Provisional schedule for the delisting: January 7, 2026 Application for delisting submitted to the Spotlight Stock Market January 8, 2026 Spotlight Stock Market approves the delisting and announces the last day of trading in the Company's shares on the Spotlight Stock Market January 8, 2026 The Company publishes a press release regarding the approval of the delisting and the last day of trading January 22, 2026 Expected last day of trading for the Company's shares on the Spotlight Stock Market The proposal was adopted unanimously and with all votes cast. ------ The meeting was closed. Chairman of the General Meeting: _______________________________ Michael Kristensen
- ·17.10.I wonder if it's still up and selling and taking the loss we're now taking. Or should we have ice in our stomachs.·17.10.What is it like when you sell at a loss, in addition to having bet incorrectly?
- ·15.10.Wonder how much the pharmaceutical industry paid them to shut down🤔?·15.10.The accounts speak for themselves - the company has not been sustainable in a single account and lives off other people's money. But we can blame the pharmaceutical industry :). Just remember that the company here operates under licenses and requirements from the Danish Medicines Agency and charges sky-high prices for their products - they are part of the industry themselves.
- ·14.10.Theft of over 100 million of the shareholders' money, it's too easy but well done by Jeppe and his henchmen.·14.10.They should be behind bars, it's disgusting that idiots should be making 100 million on fraud
- ·13.10.I think it will end with a purchase offer All the shares now cost only 878,000 kr.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
25 988
Myynti
Määrä
17 981
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | NON | NON | ||
| 3 033 | DDB | NON | ||
| 2 000 | DDB | NON | ||
| 3 012 | NON | AVA | ||
| 2 083 | NON | NON |
Ylin
0,29VWAP
Alin
0,226VaihtoMäärä
0 13 586
VWAP
Ylin
0,29Alin
0,226VaihtoMäärä
0 13 586
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 5 033 | 0 | +5 033 | 0 |
| Nordea Bank Abp | 0 | 20 | −20 | 0 |
| Nordnet Bank AB | 8 553 | 10 118 | −1 565 | 5 085 |
| Avanza Bank AB | 0 | 3 448 | −3 448 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 0 | 3 448 | −3 448 | 0 |
| Nordnet Bank AB | 8 553 | 10 118 | −1 565 | 5 085 |
| Nordea Bank Abp | 0 | 20 | −20 | 0 |
| Danske Bank A/S | 5 033 | 0 | +5 033 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 27.10. | |
| 2025 Ylimääräinen yhtiökokous | 21.10. | |
| 2025 Q2-osavuosiraportti | 25.8. | |
| 2025 Q1-osavuosiraportti | 23.5. | |
| 2025 Q1-osavuosiraportti | 28.4. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
Vain PDF
8 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 27.10. | |
| 2025 Ylimääräinen yhtiökokous | 21.10. | |
| 2025 Q2-osavuosiraportti | 25.8. | |
| 2025 Q1-osavuosiraportti | 23.5. | |
| 2025 Q1-osavuosiraportti | 28.4. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·21.10. · MuokattuDanCann Pharma is now doing this legally withdrawing and using other money and their own money on shares? without bankruptcy Cannabis company Dancann Pharma is traded today, February 24, on the Spotlight Stock Market after a reverse split. The terms are 1:1,000, meaning that one thousand existing shares are combined into one share. The share is traded with an unchanged short name DANCAN and a new Isin code.·21.10.Minutes of the Extraordinary General Meeting of DanCann Pharma A/S Tue, Oct 21, 2025 10:00 CETReport this content Minutes of the Extraordinary General Meeting of DanCann Pharma A/S, CVR-no. 39 42 60 05 ("the Company") On October 21, 2025 at 09:00 (CET), an Extraordinary General Meeting of the Company was held at the Company's address, Rugvænget 5, 6823 Ansager. The agenda for the Extraordinary General Meeting was as follows: Proposal for approval of the Board of Directors' resolution of October 6, 2025 on the voluntary delisting of the Company's shares from the Spotlight Stock Market and adoption of amendments to the Articles of Association. (proposed by the Board of Directors) Attorney Michael Kristensen was appointed as chairman of the General Meeting in accordance with section 11.20 of the Company's Articles of Association. The Chairman announced that the general meeting had been duly convened when the notice of the extraordinary general meeting was given on 6 October 2025. The Chairman described the formal requirements for the notice and concluded that these had been met. The Chairman stated that a total of 75,000 votes were represented at the general meeting, all of which were represented by shareholders in physical attendance. The Chairman concluded that the general meeting had a quorum in relation to the agenda. Re 1 The Company's Board of Directors has resolved on 6 October 2025 to submit an application to Spotlight Stock Market for voluntary delisting of the Company's shares from Spotlight Stock Market in accordance with section 6.3 of the Spotlight Stock Market Regulations, provided that this extraordinary general meeting approves it by a majority of at least 2/3 of the votes cast and 2/3 of the share capital represented at the general meeting. It was therefore proposed that the extraordinary general meeting (i) approve the board of directors' decision to apply for voluntary delisting of the Company's shares from the Spotlight Stock Market and (ii) adopt the amendments to the articles of association set out in the addendum to the draft new articles of association attached as Appendix 1 (the said amendments enabling delisting of the Company's shares). The proposed amendments to the articles of association enable delisting of the Company's shares, and these ensure, among other things, that the Company's shares can be freely traded also after delisting. It was noted that the board of directors expects to submit an application for delisting of the Company's shares to the Spotlight Stock Market on 7 January 2026. Assuming that the Spotlight Stock Market approves the application for delisting, the last trading day is expected to be 22 January 2026. The shares may be traded on the Spotlight Stock Market in accordance with the rules of the Spotlight Stock Market up to and including the last trading day. It was noted that a delisting of the Company's shares from trading on the Spotlight Stock Market will mean that the Company's shares cannot be traded on the Spotlight Stock Market, and trading in the Company's shares will take place over-the-counter ("OTC"). Provisional schedule for the delisting: January 7, 2026 Application for delisting submitted to the Spotlight Stock Market January 8, 2026 Spotlight Stock Market approves the delisting and announces the last day of trading in the Company's shares on the Spotlight Stock Market January 8, 2026 The Company publishes a press release regarding the approval of the delisting and the last day of trading January 22, 2026 Expected last day of trading for the Company's shares on the Spotlight Stock Market The proposal was adopted unanimously and with all votes cast. ------ The meeting was closed. Chairman of the General Meeting: _______________________________ Michael Kristensen
- ·17.10.I wonder if it's still up and selling and taking the loss we're now taking. Or should we have ice in our stomachs.·17.10.What is it like when you sell at a loss, in addition to having bet incorrectly?
- ·15.10.Wonder how much the pharmaceutical industry paid them to shut down🤔?·15.10.The accounts speak for themselves - the company has not been sustainable in a single account and lives off other people's money. But we can blame the pharmaceutical industry :). Just remember that the company here operates under licenses and requirements from the Danish Medicines Agency and charges sky-high prices for their products - they are part of the industry themselves.
- ·14.10.Theft of over 100 million of the shareholders' money, it's too easy but well done by Jeppe and his henchmen.·14.10.They should be behind bars, it's disgusting that idiots should be making 100 million on fraud
- ·13.10.I think it will end with a purchase offer All the shares now cost only 878,000 kr.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
25 988
Myynti
Määrä
17 981
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | NON | NON | ||
| 3 033 | DDB | NON | ||
| 2 000 | DDB | NON | ||
| 3 012 | NON | AVA | ||
| 2 083 | NON | NON |
Ylin
0,29VWAP
Alin
0,226VaihtoMäärä
0 13 586
VWAP
Ylin
0,29Alin
0,226VaihtoMäärä
0 13 586
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 5 033 | 0 | +5 033 | 0 |
| Nordea Bank Abp | 0 | 20 | −20 | 0 |
| Nordnet Bank AB | 8 553 | 10 118 | −1 565 | 5 085 |
| Avanza Bank AB | 0 | 3 448 | −3 448 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 0 | 3 448 | −3 448 | 0 |
| Nordnet Bank AB | 8 553 | 10 118 | −1 565 | 5 085 |
| Nordea Bank Abp | 0 | 20 | −20 | 0 |
| Danske Bank A/S | 5 033 | 0 | +5 033 | 0 |